Biotech: Page
-
Permission granted by Odyssey Therapeutics
Odyssey recruits new investors to fund precision drug research
A $168 million Series B round brings Odyssey’s total funding to date near $400 million, helping the startup support a growing pipeline of cancer and immune disease drug candidates.
By Ned Pagliarulo • Oct. 13, 2022 -
Permission granted by Nimbus Therapeutics
Nimbus partners with Eli Lilly on metabolic disease research
While Nimbus has drawn attention for its work on a TYK2 inhibitor, Lilly is interested in the company’s research around an enzyme called AMPK that’s seen as a useful, but hard-to-reach drug target.
By Delilah Alvarado • Oct. 12, 2022 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases or in reprogramming cells inside the body.
By BioPharma Dive staff -
Maddie Meyer via Getty Images
Merck pays $250M to license Moderna cancer vaccine
The drugmaker’s decision to grab rights to the shot deepens its ties with the COVID-19 vaccine developer and comes weeks before a key data release.
By Kristin Jensen • Oct. 12, 2022 -
Permission granted by Vertex Pharmaceuticals
Vertex, after setbacks, moves forward with second-generation rare disease drug
The biotech is starting a trial of a new treatment for alpha-1 antitrypsin deficiency following disappointing study results for two earlier compounds.
By Ned Pagliarulo • Oct. 11, 2022 -
Courtesy of Biotechnology Innovation Organization
BIO’s McMurry-Heath steps down as head of biotech lobby
Her exit from the role follows reported disagreements over the group’s direction. Former GlycoMimetics CEO Rachel King will serve as interim CEO during the search for a successor.
By Ned Pagliarulo • Oct. 11, 2022 -
Kena Betancur via Getty Images
A young biotech’s shares soar on early psoriasis drug results
Study data from Dice Therapeutics, which went public just a year ago, suggest its experimental pill has a chance to challenge marketed drugs from Amgen and Bristol Myers.
By Jonathan Gardner • Oct. 11, 2022 -
Permission granted by Neumora Therapeutics
Brain disease startup Neumora draws more funding for ambitious research plan
Launched last year to change how drugs for brain diseases are made, the biotech has now raised about $650 million to build a pipeline that includes two clinical-stage medicines.
By Gwendolyn Wu • Oct. 11, 2022 -
Courtesy of Bristol Myers Squibb
State of PlayNew TYK2 inhibitors: a growing race to top Bristol Myers
The pharmaceutical company’s psoriasis drug Sotyktu was the first of its kind to win approval. A group of well-funded startups think they can do better.
By Gwendolyn Wu • Oct. 11, 2022 -
PureTech, Nektar end talks of combination
Days after acknowledging that discussions were taking place, the two companies have called off further negotiations over a possible deal, leaving Nektar’s future again uncertain.
By Jonathan Gardner • Updated Oct. 11, 2022 -
Courtesy of BioMarin Pharmaceutical
BioMarin to lay off about 120 employees as part of restructuring plan
BioMarin said the reorganization is meant to reflect its transition to a large-scale biopharmaceutical company with a more diversified portfolio.
By Jacob Bell • Oct. 7, 2022 -
Getty Images
A Versant-backed biotech emerges to take on ‘overlooked’ cancer targets
Nested Therapeutics touts a roster of scientific leaders, including Kevan Shokat, whose work drugging KRAS — a cancer-related gene once thought to be undruggable — helped lead to Amgen’s Lumakras.
By Jacob Bell • Oct. 6, 2022 -
Illustration: Niklas Elmehed/Nobel Prize Outreach ©
Nobel Prize in chemistry awarded to biotech founder Bertozzi, two others
Carolyn Bertozzi, a Stanford scientist and co-founder of several biotechs, helped advance "click chemistry" — a concept pioneered by Morten Meldal and Barry Sharpless, with whom she shares this year's prize.
By Delilah Alvarado • Oct. 5, 2022 -
Courtesy of Biohaven Ltd.
Biohaven starts life as new company following Pfizer buyout
Spun out as part of Pfizer’s $11.6 billion acquisition, the biotech retains a pipeline of experimental neuroscience drugs and holds $258 million in cash.
By Ned Pagliarulo • Oct. 5, 2022 -
Spencer Platt via Getty Images
KalVista stops work on rare disease drug over safety concerns
The biotech terminated a Phase 2 study after treatment led to serious liver enzyme elevations in multiple patients with hereditary angioedema.
By Ned Pagliarulo • Oct. 4, 2022 -
Permission granted by Spark Therapeutics
Former Spark CEO Marrazzo joins epigenetics startup’s board
Chroma Medicine, which launched last year with $125 million in funding, has drawn several high-profile biotech leaders, including ex-Alnylam CEO John Maraganore and deal maven George Golumbeski.
By Ned Pagliarulo • Oct. 4, 2022 -
Permission granted by Cellarity
A Flagship startup secures $121M in new funding
Cellarity is the second Flagship company in as many months to raise a Series C round instead of filing to go public.
By Gwendolyn Wu • Oct. 4, 2022 -
Permission granted by Incyte
Incyte, branching out in dermatology, to buy startup Villaris
The acquisition, Incyte’s first of an entire company, hands the pharmaceutical company a potentially long lasting treatment for the skin disease vitiligo.
By Gwendolyn Wu • Oct. 3, 2022 -
Spencer Platt via Getty Images
Myovant rejects $2.4B buyout offer from Japanese majority owner
The biotech said the proposed offer “significantly undervalues” the company, but that it’s open to considering a higher bid.
By Christopher Newman • Oct. 3, 2022 -
Lisa Maree Williams via Getty Images
AstraZeneca to acquire gene editing biotech LogicBio
Shares in LogicBio had lost nearly all their value since a 2018 IPO, bringing the company to the brink of Nasdaq delisting. The buyout deal represents a premium of over 600%.
By Delilah Alvarado • Oct. 3, 2022 -
Getty Images
Solid Bio yields to Sarepta on Duchenne with plans for merger, R&D shakeup
The biotech, which fell behind Sarepta in developing a Duchenne gene therapy, will merge with AavantiBio, a startup run by a former Sarepta executive.
By Ben Fidler • Sept. 30, 2022 -
Anne Callahan/BioPharma Dive
Sponsored by TD2 Precision Oncology[PODCAST] Evolution and Innovation in Oncology Therapeutics Development
The “Evolution and Innovation in Oncology Therapeutics Development” podcast series explores the role of multi-biomarkers in precision oncology.
By BioPharma Dive's studioID • Updated Sept. 11, 2023 -
Permission granted by Amylyx Pharmaceuticals
ALS drug developmentALS drug approved by FDA in closely watched decision, marking win for patients, developer
The drug, which will be sold as Relyvrio, showed modest benefits in function and survival in testing. It also became the latest test of the FDA's flexibility toward new therapies for neurological disorders.
By Jacob Bell • Updated Sept. 30, 2022 -
Getty Images
Sudo joins a wave of startups taking aim at Bristol Myers’ new skin disease drug
The startup, which emerged Wednesday with $37 million in funding, is the latest company trying to top Bristol Myers’ TYK2 inhibitor Sotyktu.
By Gwendolyn Wu • Sept. 28, 2022 -
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
New Alzheimer's drugsIn surprise result, Alzheimer’s drug from Eisai, Biogen shows benefit in large trial
The companies’ drug lecanemab met all of its goals in the Phase 3 study. The data were a significant finding and provided stronger support for a much-debated hypothesis for treating Alzheimer’s.
By Jonathan Gardner • Updated Sept. 27, 2022 -
Courtesy of Vertex Pharmaceuticals
Vertex given green light to seek US approval of CRISPR-based therapy
The company and its development partner, CRISPR Therapeutics, will begin submitting a rolling application in November. The blood disease treatment is the first of its kind to near an FDA review.
By Jacob Bell • Sept. 27, 2022
Previous
